You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: May 23, 2025

CLINICAL TRIALS PROFILE FOR COLCHICINE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Colchicine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000577 ↗ Asthma Clinical Research Network (ACRN) Withdrawn National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1993-09-01 This study will establish a network of interactive asthma clinical research groups to evaluate current therapies, new therapies, and management strategies for adult asthma.
NCT00000577 ↗ Asthma Clinical Research Network (ACRN) Withdrawn Milton S. Hershey Medical Center Phase 3 1993-09-01 This study will establish a network of interactive asthma clinical research groups to evaluate current therapies, new therapies, and management strategies for adult asthma.
NCT00004368 ↗ Phase I Study of Colchicine Therapy in Childhood Hepatic Cirrhosis Unknown status Children's Hospital Colorado Phase 1 1990-05-01 OBJECTIVES: I. Investigate the efficacy and safety of colchicine therapy in improving hepatic function and reducing hepatic fibrosis (scarring) in children with hepatic cirrhosis.
NCT00004368 ↗ Phase I Study of Colchicine Therapy in Childhood Hepatic Cirrhosis Unknown status National Center for Research Resources (NCRR) Phase 1 1990-05-01 OBJECTIVES: I. Investigate the efficacy and safety of colchicine therapy in improving hepatic function and reducing hepatic fibrosis (scarring) in children with hepatic cirrhosis.
NCT00004748 ↗ Low-Dose Oral Methotrexate Versus Colchicine for Primary Biliary Cirrhosis Completed Tufts Medical Center Phase 3 1989-11-01 OBJECTIVES: I. Compare the efficacy of low-dose oral pulse methotrexate (MTX) and ursodiol versus colchicine and ursodiol in patients with primary biliary cirrhosis (PBC). II. Determine the optimum dose and duration of MTX treatment. III. Investigate the role of fibrogenic cytokines (FC) in PBC pathogenesis and the effect of treatment on FC production.
NCT00004748 ↗ Low-Dose Oral Methotrexate Versus Colchicine for Primary Biliary Cirrhosis Completed National Center for Research Resources (NCRR) Phase 3 1989-11-01 OBJECTIVES: I. Compare the efficacy of low-dose oral pulse methotrexate (MTX) and ursodiol versus colchicine and ursodiol in patients with primary biliary cirrhosis (PBC). II. Determine the optimum dose and duration of MTX treatment. III. Investigate the role of fibrogenic cytokines (FC) in PBC pathogenesis and the effect of treatment on FC production.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Colchicine

Condition Name

Condition Name for Colchicine
Intervention Trials
Gout 26
Coronary Artery Disease 14
Pharmacokinetics 13
Atrial Fibrillation 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Colchicine
Intervention Trials
Gout 33
COVID-19 30
Inflammation 24
Atrial Fibrillation 17
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Colchicine

Trials by Country

Trials by Country for Colchicine
Location Trials
United States 415
Canada 38
Italy 35
China 30
France 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Colchicine
Location Trials
California 28
New York 26
Texas 21
Florida 21
North Carolina 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Colchicine

Clinical Trial Phase

Clinical Trial Phase for Colchicine
Clinical Trial Phase Trials
Phase 4 45
Phase 3 71
Phase 2/Phase 3 12
[disabled in preview] 111
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Colchicine
Clinical Trial Phase Trials
Completed 103
Recruiting 65
Not yet recruiting 38
[disabled in preview] 41
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Colchicine

Sponsor Name

Sponsor Name for Colchicine
Sponsor Trials
Mutual Pharmaceutical Company, Inc. 20
Population Health Research Institute 10
Novartis Pharmaceuticals 8
[disabled in preview] 23
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Colchicine
Sponsor Trials
Other 350
Industry 75
NIH 17
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Colchicine: Clinical Trials, Market Analysis, and Projections

Introduction to Colchicine

Colchicine is an oral medication that has been used for centuries, primarily for the treatment of gout and other inflammatory conditions. Recently, it has been explored for its potential benefits in cardiovascular diseases. Here, we will delve into the latest clinical trials, market analysis, and projections for colchicine.

Clinical Trials Update: CLEAR SYNERGY Trial

One of the most significant recent developments in the clinical use of colchicine is the results from the CLEAR SYNERGY (OASIS 9) trial. This large, randomized controlled trial investigated the efficacy of low-dose colchicine in patients who had experienced an acute myocardial infarction (MI)[1][4].

Key Findings of the CLEAR SYNERGY Trial

  • The trial involved a placebo-controlled factorial design and was the largest to date on this subject, with 649 outcome events.
  • The results showed that routine administration of colchicine did not reduce cardiovascular death, myocardial infarction, stroke, or ischemia-driven revascularization in patients post-MI.
  • Despite earlier smaller studies suggesting potential benefits, the CLEAR SYNERGY trial found no significant reduction in cardiovascular outcomes.
  • Additionally, the trial highlighted a common side effect of colchicine: diarrhea[1][4].

Expert Opinions and Implications

Dr. Sanjit S. Jolly, the principal investigator, noted that the findings should give clinicians pause and reconsider the use of colchicine in post-MI patients. Dr. Jolly, who had previously believed in colchicine’s effectiveness based on earlier trials, even removed his father from the medication following these results[1].

However, not all experts agree on the implications. Dr. Jean-Claude Tardif suggested that any changes to current guidelines based on this trial would be premature, citing the disruption caused by the COVID-19 pandemic during the trial period. He pointed out that subgroup analysis suggested a potential benefit of colchicine before the pandemic, although this was not statistically significant[1].

Market Analysis of Colchicine

The colchicine market is experiencing significant growth driven by several factors.

Market Size and Growth Projections

  • The global colchicine market was valued at USD 1.46 billion in 2023 and is expected to reach USD 1.58 billion in 2024. It is projected to grow at a CAGR of 7.85% to USD 2.49 billion by 2030[2].
  • Another report estimates the market size to reach USD 2,552.84 million by 2030, with a CAGR of 8.4%[3].
  • IndustryARC projects the market to reach $1,558.9 million by 2030, growing at a CAGR of 6.56% during the forecast period 2023-2030[5].

Key Drivers of Market Growth

  • Increasing Incidence of Gout and Related Diseases: The rising prevalence of gout, Familial Mediterranean Fever (FMF), and other related diseases is a major driver of market growth[3][5].
  • Clinical Trials and Therapeutic Expansions: The increase in clinical trials for colchicine has expanded its potential therapeutic applications, including cardiovascular diseases and COVID-19 symptom treatment[3].
  • Geographic Dominance: North America, particularly the United States, dominates the colchicine market due to advanced healthcare infrastructure, high prevalence of gout, and strong pharmaceutical sector support[5].

Market Dynamics and Trends

  • The market is influenced by a dynamic interplay of supply and demand factors, including consumer behavior, manufacturing costs, and purchasing trends.
  • Porter's Five Forces analysis is crucial for navigating the colchicine market, helping businesses make informed investment decisions and strategic choices[2].

Applications of Colchicine Beyond Gout

While gout remains the primary indication for colchicine, the drug is being explored for various other conditions.

Cardiovascular Diseases

Despite the neutral results from the CLEAR SYNERGY trial, earlier studies had suggested potential benefits of colchicine in reducing inflammation in cardiovascular diseases. However, its role in long-term post-MI use is now uncertain[1][4].

Other Therapeutic Uses

Colchicine is also used in the treatment of conditions such as Behcet’s Disease, Dermatitis Herpetiformis, FMF, and pericarditis. The increasing focus on these therapeutic alternatives is driving market growth[3][5].

Regulatory and Pharmaceutical Sector Impact

Regulatory Approval and Availability

The U.S. Food and Drug Administration (FDA) has approved colchicine for several indications, contributing to its widespread availability in the North American market. The strong pharmaceutical sector in the U.S. supports both branded and generic drug manufacturers, further boosting market growth[5].

Funding and Sponsorship

Clinical trials such as the CLEAR SYNERGY trial are often sponsored by research institutions and funded by health research organizations and pharmaceutical companies. For example, the CLEAR SYNERGY trial was sponsored by the Population Health Research Institute (PHRI) and funded by the Canadian Institutes of Health Research and Boston Scientific[4].

Conclusion

The colchicine market is complex and dynamic, influenced by clinical trial outcomes, market demand, and regulatory factors.

Key Takeaways

  • Clinical Trials: The CLEAR SYNERGY trial showed no significant benefit of colchicine in reducing cardiovascular outcomes post-MI, contrary to earlier smaller studies.
  • Market Growth: The global colchicine market is projected to grow significantly, driven by increasing incidence of gout and other related diseases, and expanding therapeutic applications.
  • Geographic Dominance: North America, particularly the U.S., dominates the market due to advanced healthcare infrastructure and a strong pharmaceutical sector.
  • Regulatory and Pharmaceutical Impact: FDA approval and strong pharmaceutical sector support contribute to the market growth and availability of colchicine.

FAQs

What were the main findings of the CLEAR SYNERGY trial?

The CLEAR SYNERGY trial found that routine administration of colchicine did not reduce cardiovascular death, myocardial infarction, stroke, or ischemia-driven revascularization in patients post-MI.

What is driving the growth of the colchicine market?

The growth is driven by the increasing incidence of gout and related diseases, expanding therapeutic applications, and strong demand in regions like North America.

What are the common side effects of colchicine?

One of the common side effects highlighted in the CLEAR SYNERGY trial was diarrhea.

Is colchicine approved by regulatory bodies for various indications?

Yes, colchicine is approved by the FDA for several indications, including gout and FMF.

What is the projected market size of colchicine by 2030?

The projected market size varies by report, but it is estimated to reach between $1,558.9 million and $2,552.84 million by 2030.

Sources

  1. tctmd.com: "No Help Post-MI, Large CLEAR SYNERGY Trial Shows"
  2. giiresearch.com: "Colchicine Market by Dosage Formulation, Age, Route of Administration"
  3. biospace.com: "Colchicine Market Size 2022-2030- Increasing Clinical Studies Of Colchicine Drugs For Various Applications"
  4. crf.org: "Routine Colchicine Administration After Acute Myocardial Infarction Does Not Improve Outcomes"
  5. industryarc.com: "Colchicine Market - Forecast(2024 - 2030)"
Last updated: 2024-12-31

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.